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Abstract
Background: Although the association between mitral stenosis (MS) and increased coagulation
activity is well recognized, it is unclear whether enhanced coagulation remains localized in the left
atrium or whether this represents a systemic problem. To assess systemic coagulation parameters
and changes in platelet aggregation, we measured fibrinogen levels and performed in vitro platelet
function tests in plasma obtained from mitral stenotic patients' and from healthy control subjects'
peripheral venous blood.
Methods: Sixteen newly diagnosed patients with rheumatic MS (Group P) and 16 healthy subjects
(Group N) were enrolled in the study. Platelet-equalized plasma samples were evaluated to
determine in vitro platelet function, using adenosine diphosphate (ADP), collagen and epinephrine
in an automated aggregometer. In vitro platelet function tests in group N were performed twice,
with and without plasma obtained from group P.
Results: There were no significant differences between the groups with respect to demographic
variables. Peripheral venous fibrinogen levels in Group P were not significantly different from those
in Group N. Adenosine diphosphate, epinephrine and collagen-induced platelet aggregation ratios
were significantly higher in Group P than in Group N. When plasma obtained from Group P was
added to Group N subjects' platelets, ADP and collagen-induced, but not epinephrine-induced,
aggregation ratios were significantly increased compared to baseline levels in Group N.
Conclusion: Platelet aggregation is increased in patients with MS, while fibrinogen levels remain
similar to controls. We conclude that mitral stenotic patients exhibit increased systemic
coagulation activity and that plasma extracted from these patients may contain some transferable
factors that activate platelet aggregation.
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Introduction
Systemic thromboembolism represents a major complica-
tion in patients with mitral stenosis (MS), especially in
those who have atrial fibrillation [1,2]. A hypercoagulable
state has been reported in patients with MS and sinus
rhythm [3,4]. The association between MS and higher lev-
els of coagulation is well-known; however, the source of
increased coagulation remains unclear. Increased regional
left atrial coagulation activity may be involved, even when
systemic coagulation assessed by peripheral blood sam-
pling is normal [5,6]. Others have reported no significant
variation in thrombogenesis, platelet activation, and
endothelial dysfunction between the left atrium, right
atrium and peripheral arteries or veins [7].
This study assessed systemic coagulation and platelet
activities by measuring fibrinogen levels and platelet
aggregation in mitral stenotic patients' peripheral venous
blood and compared these measures to hematologic
parameters in normal controls.
Methods
Study groups
Eighteen newly diagnosed patients with rheumatic MS
were enrolled in the study. All were coded as having
NYHA class I functional capacities. Two patients were
excluded from this study, one due to pregnancy, the sec-
ond due to current use of oral contraceptives. The study
group thus consisted of 16 patients with MS (Group P, 14
female, 2 male, mean age 27.8 ± 6.5 years). Peripheral
venous coagulation activity and platelet activation tests
were also evaluated in 16 control patients (Group N, 13
female, 3 male, mean age 28.3 ± 6.1 years), who were nor-
mal volunteers. All participants gave informed consent.
Exclusion criteria
Patients were excluded from participating in the study for
the following reasons: aortic and/or pulmonary valve dis-
ease, severe mitral regurgitation and/or left ventricular
systolic dysfunction, atrial fibrillation, hypertension, dia-
betes mellitus, dyslipidemia, a history of renal or liver dis-
ease, malignancy, venous thrombosis, systemic or
pulmonary embolism, congenital hemorrhagic disease,
thrombocytopenia, thrombocytosis, acute or chronic
inflammatory disease, autoimmune disease or current use
of oral contraceptives or anticoagulant or anti-platelet
drugs.
Echocardiography
In patients with MS, transthoracic echocardiography was
performed with a 2.5-MHz transducer and a Hewlett Pack-
ard Sonos 4500 system to assess left atrial (LA) diameter,
mitral valve area (MVA) and the transmitral mean pres-
sure gradient (TMmPG). The LA anteroposterior diameter
was determined using standard M-mode criteria [8], and
mitral valve area was calculated according to the pressure
half-time method [9].
Fibrinogen measurement
Peripheral venous blood (for measurement of fibrinogen
levels) was transferred into tubes containing 1:9 triso-
dium citrate (0.109 M, 3.2%). Blood samples were centri-
fuged within 1 hour of collection at 2,500 g for 10
minutes to separate out the plasma. An STA fibrinogen kit
measured fibrinogen levels in plasma, using the clotting
method of Clauss. The median inter-assay and intra-assay
coefficients of variation for the assays were 3.57% and
3.65% for fibrinogen, respectively.
Platelet activation tests
Blood samples were obtained from the forearm veins of
participants, using standard blood drawing procedures
(normal blood flow and no pressure). Several samples
were drawn for different components of the study. Nine
milliliters of blood was collected into special tubes con-
taining 1 ml of 3.8% sodium citrate. Platelet count and
other parameters, including white blood cell count and
hemoglobin, were measured at the Ege University Hospi-
tal Hematology Laboratory using an automated hemocy-
tometer (Cell Dyne 4000 Abbott, USA). Patients with
platelet counts less than 2 × 105/ml were excluded from
the study. For in vitro platelet aggregation tests, platelet-
rich plasma (PRP) samples were obtained by centrifuging
samples at 1,100 rpm for 10 minutes in a refrigerated cen-
trifuge (Hettich EBA 12R, Germany). Centrifuging sam-
ples at 3,000 rpm for 10 minutes yielded platelet-poor
plasma (PPP) samples. The platelet counts of both PRP
and PPP samples were performed using the same hemocy-
tometer. Platelet-poor plasma samples were added to the
PRP samples to obtain a total platelet count of 2 × 105/ml.
These platelet-equalized plasma (PEP) samples were ana-
lyzed to determine in vitro platelet function, using ADP,
Collagen and Epinephrine (all from Bio/Data Corp. Hor-
shram, Germany) in an automated aggregometer (Bio/
Data Corp. Platelet Agregation Profiler, Horshram-Ger-
many). Results were evaluated and calculated using maxi-
mum aggregation ratios.
PRP from healthy controls was centrifuged for 10 min-
utes, after which the supernatant was decanted, and nor-
mal saline added to the platelet fraction and centrifuged
for 10 minutes. This procedure was repeated three times.
Plasma obtained from patients with MS was added to the
PPP from the control group, and platelet function tests
were performed, using the same procedures mentioned
above.
Statistical analyses
Chi Square tests were employed to compare categorical
variables, while Mann Whitney U tests were used, whereCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:2 http://cvm.controlled-trials.com/content/6/1/2
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appropriate, in the univariate analysis. Platelet aggrega-
tion changes were evaluated by repeated-measures analy-
sis of variance for intra-group comparisons. Values of p <
0.05 were considered significant. SPSS 10.0 Statistical
software was used in the statistical analysis.
Results
There were no significant differences between Groups P
and N for the following variables: age, gender, current
smoker, platelet, white blood cell and hemoglobin count.
Clinical characteristics of the study groups are shown in
Table 1. The peripheral venous fibrinogen levels in
patients with MS (301.9 ± 53.7 mg/dL) were not signifi-
cantly different from those in control subjects (284.6 ±
55.7 mg/dL).
Platelet activation tests
Adenosine diphosphate, collagen and epinephrine-
induced platelet aggregation ratios were significantly
higher in Group P than in Group N (84.9 ± 9.8, 76.6 ±
21.4, 80 ± 10.5 and 53.1 ± 23.2, 47.5 ± 14.5, 53.7 ± 21.3,
p < 0.05, respectively). When the PPP obtained from
Group P was added to Group N subjects' platelets, and
platelet function tests were repeated, ADP and collagen-
induced (73 ± 17.5 and 65.7 ± 17.5, respectively), but not
epinephrine-induced (61.9 ± 16.2), aggregation ratios
were statistically increased compared to baseline (Figure
1).
Discussion
Left atrial thrombus in MS is associated with increased sys-
temic levels of peptide by-products from the coagulation
cascade [10,11]. Increases in markers of coagulation activ-
ity may also occur in the absence of thrombus, perhaps
signifying that an imbalance in hemostatic regulation
favoring pro-coagulant mechanisms may precede and pre-
dispose to thrombus formation [12,13]. Information
about coagulation activity in patients with MS could,
therefore, provide a method of identifying patients at risk
of developing systemic thromboembolism.
A number of studies have reported that indexes of hyper-
coagulation derived from peripheral blood may not
reflect intracardiac thrombogenesis. Yamamoto et al. [6]
noted that fibrinopeptide A and thrombin/antithrombin
III were higher in the left atrium compared to the right
atrium and the femoral vein. Peverill et al. [5] found that
levels of prothrombin fragments 1+2 increased in the left
atrium in comparison to peripheral blood levels. Li-Saw-
Hee et al. [7] reported no significant variation in indexes
of thrombogenesis, platelet activation, and endothelial
dysfunction between left atrium, right atrium, and the
peripheral artery or vein. A number of differences between
these studies and our study may, in part, account for these
varying observations. All of our patients exhibited newly
diagnosed, mild-to- moderate MS, and none was taking
anticoagulants or anti-platelet drugs. Second, we did not
investigate systemic levels of peptide by-products of the
coagulation cascade or individual blood components that
reflect coagulability. In our experimental design, we
sought to examine the effect of mitral stenotic patients'
plasma on control subjects' platelets.
In addition to protein factors, platelets play a vital role as
systemic components of the hemostatic system. They are
critical to the activation of intrinsic pathway factors.
Because platelet activation seems to be influenced by dia-
betes mellitus [14], smoking [15], hypertension and the
Table 1: Clinical features of the study groups and echocardiographic findings of patients with mitral stenosis.
Group P (n = 16) Group N (n = 16) p
Mean age (yrs) 27.8 ± 6.5 28.3 ± 6.1 NS
Male/female (n) 2/14 3/13 NS
Current smoker (n) 56 N S
Platelet count × 103/mm3 253.1 ± 33.5 245.6 ± 34.3 NS
WBC/mm3 5706 ± 1266 5643 ± 1229 NS
Hb (g/L) 12.4 ± 1.26 12.8 ± 1.22 NS
Fibrinogen (mg/dL) 301.9 ± 53.7 284.6 ± 55.7 NS
LA diameter (cm) 4.22 ± 0.19 - -
MVA (cm2) 1.67 ± 0.16 - -
TMmPG (mmHg) 6.5 ± 0.96 - -
Mitral regurgitation (n)
None 4 - -
Mild 11 - -
Moderate 1 - -
Group P: Patients with mitral stenosis, Group N: Control subjects, WBC: White blood cell, Hb: Hemoglobin, LA: Left atrium, MVA: Mitral 
valve area, TMmPG: Transmitral mean pressure gradient, NS: Non-significant.Current Controlled Trials in Cardiovascular Medicine 2005, 6:2 http://cvm.controlled-trials.com/content/6/1/2
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use of oral contraceptives [16], patients with these condi-
tions were excluded from our study.
Hwang et al. [17] sought to examine a correlation among
echocardiographic variables, hematologic parameters or
platelet aggregability and the occurrence of spontaneous
echo-contrast (SEC) in the left atrium. Platelet aggregabil-
ity was evaluated with a turbidometric method, using dif-
ferent concentrations of activating agents. No significant
difference was found in platelet aggregability between
patients with left atrial SEC and patients without left atrial
SEC. Neither group of patients had been receiving anti-
platelet or anticoagulant therapy.
Ileri et al. [4] observed hypercoagulation in patients with
mitral stenosis and sinus rhythm when SEC was present.
Pongratz et al. [18] investigated the activation status of
platelets in the peripheral blood of patients with atrial
fibrillation. A significantly higher level of circulating
platelets expressing P-selectin and CD63 and more leuko-
cyte-platelet conjugates were found in patients positive for
both SEC and left atrial thrombus or embolic events.
Increased spontaneous platelet aggregation in the pres-
ence of SEC was described by Rohmann et al. [19], who
measured the half-maximal formation of platelet aggre-
gates in peripheral blood, upon stimulation with ADP.
In our study, all patients had mild-to-moderate MS, with
functional capacities rated as being NYHA class I.
Although peripheral fibrinogen levels were similar
between Group P and N, platelet aggregation was signifi-
cantly higher in Group P than in Group N. Moreover,
alteration of platelet aggregation in Group N, triggered by
the addition of plasma from mitral stenotic patients, may
indicate the presence of possible transferable platelet acti-
vators in peripheral blood.
Induced platelet aggregation ratios in Groups P and N Figure 1
Induced platelet aggregation ratios in Groups P and N. Group P: Patients with mitral stenosis, Group N: Control subjects, PPP: 
Platelet-poor plasma, Plt: platelet, ADP: Adenosine diphosphate, COL: Collagen, EPI: Epinephrine.Publish with BioMed Central    and   every 
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In conclusion, we examined systemic coagulation activity
in patients with MS by measuring plasma level of fibrino-
gen and by performing platelet activation tests in periph-
eral venous blood samples. Our examinations yielded
three main findings. First, mitral stenotic patients have
similar fibrinogen levels in peripheral venous blood as
compared to controls. Second, platelet aggregation is
higher in patients with MS than in controls. Third, in com-
parison to controls, patients with MS have increased sys-
temic coagulation activity and the plasma extracted from
these patients seems to have some transferable factors that
activate platelets.
The results from this study emphasize the complexity of
the events related to platelet activation in MS. Also com-
pounding the challenges faced in this area is uncertainty
about the gold standard method for assessing platelet acti-
vation and whether platelet aggregation (ex vivo) truly
reflects platelet activation in vivo [20].
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